Algeria vs Barbados: Access to anti-retroviral drugs, female
Algeria
65.0%
in 2024
Barbados
67.0%
in 2024
Algeria rank
91st
Barbados rank
88th
Access to anti-retroviral drugs, female over time
- Algeria
- Barbados
How they compare
Barbados currently reports 67.0% against 65.0% in Algeria, a difference of 2.0%.
The two have swapped places 3 times across 25 shared years of data; in 2000 it was Algeria ahead.
Algeria ranks 91st and Barbados ranks 88th of 141 countries.
Across the 3 decades both report, Algeria averaged higher in 1 and Barbados in 2.
Head to head by decade
| Decade | Algeria | Barbados | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 6.7% | 20.4% | 13.7% | Barbados |
| 2010s | 47.5% | 51.6% | 4.1% | Barbados |
| 2020s | 68.6% | 65.8% | 2.8% | Algeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Algeria or Barbados?
- Barbados, at 67.0% against 65.0% in Algeria as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Algeria and Barbados?
- 2.0%, with Barbados ahead.
- How many years of comparable data are there for Algeria and Barbados?
- 25 years are reported by both, from 2000 to 2024.
- How do Algeria and Barbados rank globally for access to anti-retroviral drugs, female?
- Algeria ranks 91st and Barbados ranks 88th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.